Anlon Healthcare Limited has filed a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
The company has incorporated a new wholly-owned subsidiary named Anlon Biologics Private Limited (CIN: U21000GJ2026PTC180405). The incorporation was effective from July 10, 2026.
Key Details of the Subsidiary
- Date of Incorporation: July 10, 2026
- Country of Incorporation: India
- Industry: Pharmaceuticals
- Authorized Share Capital: ₹1,000,000 (Rupees Ten Lakh)
- Paid-up Share Capital: ₹1,000,000 (Rupees Ten Lakh)
- Turnover: Nil, as it is a newly incorporated company yet to commence business.
Transaction Details
- Consideration Form: Cash / banking channel
- Cost of Subscription: Anlon Healthcare Limited subscribed to shares for an aggregate amount of ₹650,000 (Rupees Six Lakh Fifty Thousand).
- Shares Subscribed: 65,000 (Sixty Five Thousand) equity shares of face value ₹10 each.
- Resulting Shareholding: This subscription gives Anlon Healthcare Limited a 65% shareholding in the subsidiary.
Strategic Purpose and Impact
The purpose of incorporating this subsidiary is aligned with the company's long-term growth objectives. The subsidiary will be engaged in the development and manufacture of peptides, biosimilars, biological compositions, and surgical implants/medical devices. The company intends to leverage this opportunity to strategically complement and expand its existing business in the pain management segment, positioning itself to benefit from anticipated growth in this sector.
The disclosure confirms that this incorporation does not constitute a related party transaction, and no governmental or regulatory approvals were required for this action.